Shawn L Fultz, MD MPH VACS Scientific Meeting, Feb 2004

Slides:



Advertisements
Similar presentations
A Prognostic Index for those Aging with HIV: Extension of the VACS Index to those on Combination Anti-Retroviral Therapy (cART) AC Justice* 1,2, S Modur.
Advertisements

HIV Disease in Older Patients Donna M. Gallagher, ANP The International AIDS Society–USA DM Gallagher, ANP. Presented at IAS–USA/RWCA Clinical Conference,
Gender and the use of Veterans Health Administration homeless services programs among Iraq/Afghanistan Veterans Oni J. Blackstock, MD Yale RWJF Clinical.
Introduction DCDOH supports HIV test and treat activities - increased number of HIV tests performed, emphasis on earlier linkage to care. Limited data.
Patient Empowerment Impacts Medication Adherence among HIV-Positive Patients in the Veteran’s Health Administration Tan Pham 1,2,3, Kristin Mattocks 1,2,
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
Is monitoring for CD4 counts still needed for the management of patients with long- term HIV RNA suppression? Andrew Hill, Liverpool University, UK.
The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.
Complete Recovery of Renal Function After Acute Kidney Injury is Associated with Long-Term All-Cause Mortality In a Large Managed Care Organization Jennifer.
Thomas S. Rector, PhD, Inder S. Anand, MD, David Nelson, PhD, Kristine Ensrud, MD and Ann Bangerter, MS CHF QUERI NETWORK November 8, 2007 VA Medical Center,
Fatal and Non-fatal Hepatic Failure in HIV-infected versus HIV-uninfected Persons Enrolled in Kaiser Permanente California (KP), a Large Managed Care Organization.
Catherine Kober Margaret Johnson Martin Fisher Caroline Sabin On behalf of UK-CHIC BHIVA/BASHH Manchester 2010 Non-uptake of HAART among patients with.
Management and Development for Health (MDH)
Black Patients Die Earlier after Surgery for Esophageal Cancer Andrea S. Wolf, MD, MPH, Emanuela Taioli MD, PhD, Marlene Camacho-Rivera, ScD, MPH, Andrew.
HIV/renal studies (CHIC) Baseline renal function as predictor of HIV/renal disease progression –Death, opportunistic infection –Severe chronic kidney disease.
Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.
Generously supported by the Robert Wood Johnson Foundation Clinical Scholars Program, Department of Veteran Affairs, and National Institutes of Health,
David Dowdy, Elvin Geng, Katerina Christopoulos, James Kahn, C. Bradley Hare, Daniel Wlodarczyk, Diane Havlir Internal Medicine Residency Program, UCSF.
Supported by: NIAID/NHLBI R24 AI067039, NIAID R21 AI Viremia copy-years: A measure of cumulative HIV burden among patients initiating antiretroviral.
Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,
Survival Analysis approach in evaluating the efficacy of ARV treatment in HIV patients at the Dr GM Hospital in Tshwane, GP of S. Africa Marcus Motshwane.
Teaching Intensity, Race and Surgical Outcomes Jeffrey H. Silber The University of Pennsylvania The Children’s Hospital of Philadelphia.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
The Impact of Darunavir/ritonavir (DRV/r) & Raltegravir (RAL) in the Clinic: A New Era for Treatment-Experienced Patients? M. Mugavero 1, H. Lin 1, J.
A Survival Comparison between HIV+ U.S.-born Latinos and Foreign-born Latinos in Houston, Texas Raouf Arafat, MD, MPH, Adebowale Awosika- Olumo.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.
Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,
Earlier treatment and lower mortality in infants Initiating ART at
The Ethiopian TB HAART study: Find out the timing for ART when CD4< 200cells/µL Anything new? Wondwossen Amogne, Abiy H/ wold, Getent Yimer,
CMV viraemia and 12-week mortality among hospitalised adults with HIV-associated TB in Khayelitsha Hospital, South Africa: A prospective cohort study A.
. Troponin limit of detection plus cardiac risk stratification scores for the exclusion of myocardial infarction and 30-day adverse cardiac events in ED.
Factors affecting virological failure in patients receiving antiretroviral therapy: a prospective HIV Clinical cohort in rural Uganda. Patrick Kazooba1,
Higher rate of antiretroviral therapy reinitiation among HIV-HBV coinfected patients in the episodic arm of the SMART study Dore G.1, Soriano V.2, Neuhaus.
L.F. Jefferys1, J. Hector1, M.A. Hobbins2, J. Ehmer2, N. Anderegg3
Alina M. Allen MD, Patrick S. Kamath MD, Joseph J. Larson,
Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda
Clinical outcome after SVR: Veterans Affairs
Chronic Kidney Disease in HIV Infection: An Urban Epidemic
Juan Gonzalez Perez AIDS Healthcare Foundation
Effects of a Nationwide Predialysis Educational Program on Modality Choice, Vascular Access, and Patient Outcomes  Eduardo Lacson, MD, MPH, Weiling Wang,
Diabetes Journal Club March 17, 2011
Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II
Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens.
Management and Development for Health (MDH)
Presenter Disclosure Information
Pneumococcal Polysaccharide (PV) Vaccine Failures among HIV-infected Veterans Compared to Non-HIV-infected controls. Maria C. Rodriguez-Barradas, MD.
VACS Risk Index Refinement and further validation
Cholesterol Management in HIV-infected and Uninfected Patients: The Veterans Aging Cohort Study Leaf, DA, Goulet J, Goetz MB, Oursler KA, Gilbert C, Frieberg.
Impact of Hepatitis C, HIV, or Both on Survival in Veterans in Care Before and After the Introduction of HAART (1996) SL Fultz, MD, MPH CH Chang, PhD AA.
VACS Scientific Meeting October 15, 2008 Joseph K. Lim, M.D.
Depression Treatment in HIV-infected and Uninfected Veterans: Do Rates Vary by HIV Status? Kristen Sueoka YSM IV.
Patterns, predictors, and consequences of non-medical use prescription opioids in the Veterans Aging Cohort Study Brandon DL Marshall, PhD Manning Assistant.
The Role of Comorbidity in Long Term HIV Infection and Treatment
Hashem B. El-Serag, Thomas P
Jeffrey P. Anderson Combination Antiretroviral Therapy and Hepatic Decompensation in HIV/HCV Coinfected Veterans JEFFREY P. ANDERSON.
for the VACS Project Team
Liver Injury is Associated with ASCVD, Stroke, and CHF
Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD
<?xml version="1.0"?><AllQuestions />
Fernando Fleischman, MD, Ramsey S. Elsayed, MD, Robbin G
Survival by time of day of hemodialysis: analysis of United States renal data system dialysis morbidity and mortality waves III/IV  Kevin C Abbott, MD,
Incidence of HCC after HCV treatment with DAAs: ERCHIVES
Core Competency 1: Epidemiologic Background of HIV/HCV Co-infection in the United States Lesson 2: Morbidity and Mortality in HCV Co-infected People Living.
The impact of concomitant pulmonary hypertension on early and late outcomes following surgery for mitral stenosis  Bo Yang, MD, PhD, Christina DeBenedictus,
Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.
Dialysis outcomes in Australia & New Zealand
Receipt of medication-assisted treatment halves the risk of HIV-1 RNA viral load rebound for HIV-positive women who use illicit drugs Joëlla W. Adams,
Men’s Health Foundation, Los Angeles, CA
Share your thoughts on this presentation with #IAS2019
Presentation transcript:

Shawn L Fultz, MD MPH VACS Scientific Meeting, Feb 2004 Survival in Patients Coinfected With HIV and Hepatitis C: A CD4 Threshold Effect Shawn L Fultz, MD MPH VACS Scientific Meeting, Feb 2004

Background HIV infected patients are living longer. Comorbid disease is becoming more important for outcomes Impact of HCV coinfection is not clear: Some studies show increased mortality Some studies show no additional mortality

Background Most studies treat CD4 as continuous variable

Hypothesis HCV’s impact on mortality is dependent on a threshold CD4 count.

Methods Used combined cohort data CD4 & viral load closest to baseline VACS 3 CHORUS CD4 & viral load closest to baseline CD4 – sq root transformed Viral load – log10 transformed Stratified by CD4 count Cutpoints: 350, 200, 100, 50

Methods Kaplan-Meier curves Cox proportional hazards adjusting for: Age Sex Race Cohort CD4 Viral load

Results VACS 3 CHORUS p-value n= 865 5,543 Age, mean (SD) 48.8 (9.1) 40.1 (8.3) <0.0001 Male (%) 99 91 <0.001 Race (%) --White 34 77 --Black 54 15 --Hispanic 12 8 Alcohol Diagnosis (%) 27 5 Hepatitis C (%) 11 Median CD4 (IQR) 333 (185-510 378 (217-566) 0.0001 Median log10 VL (IQR) 2.9 (1.7-4.1) 3.1 (2.6-4.3) Follow-up, median (yrs) 2.7 4.1 Deaths (#) 83 384 Deaths/1000 person-years 38.9 20.9

Kaplan Meier – Entire Cohort

Kaplan Meier –By CD4 Strata

Cox Regression by CD4 Cutpoint ≥ 100 cells/mm3 <100 cells/mm3 HR p-value HCV 1.92 <0.001 0.72 0.2 Age 1.89 1.10 0.3 Female 0.99 0.9 1.42 0.1 Black 1.05 0.8 0.89 0.5 Hispanic 0.96 1.07 VACS 1.19 0.4 Alcohol Dx 1.49 0.03 0.98 Viral Load 1.60 1.65

Cox Models HR 95% CI Hepatitis C 1.37 1.09 – 1.75 0.92 0.60 – 1.41 Age (10 years) 1.50 1.35 – 1.66 Female 1.24 0.90 – 1.71 1.29 0.93 – 1.78 Black 0.94 0.75 – 1.18 0.93 0.74 – 1.17 Hispanic 0.89 0.63 – 1.25 0.64 – 1.26 VACS 3 1.25 0.94 – 1.65 1.23 0.93 – 1.63 Alcohol Dx 0.92 – 1.67 1.22 0.91 – 1.65 CD4 0.87 – 0.90 0.88 Viral Load 1.45 1.32 – 1.58 1.33 – 1.59 HCV-CD4 Interaction 1.82 1.12 – 2.96

Conclusions Effect of hepatitis C is dependent on CD4 count Appears to be a threshold at ~100 cells/mm3 Due to competing mortality Does not mean no HCV effect below threshold May explain conflicting results of other studies

Acknowledgements Stephen L Becker, MD Gregory P Fusco Melissa Skanderson, MSW Adeel A Butt, MD Michael O Rigsby, MD Douglas T Dieterich, MD Michael Simberkoff, MD Chung-Chou H Chang, PhD Maria C Rodriguez-Barradas, MD Amy C Justice, MD PhD